期刊
NEUROBIOLOGY OF AGING
卷 33, 期 8, 页码 1599-1608出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2011.05.005
关键词
Alzheimer's disease; Body mass index; Cerebrospinal fluid; Tau protein; A beta(1-42)
资金
- Merck
- Avid
- NIH
- DOD
- VA
- Federal Agency of Education and Research
- SFI investigator neuroimaging program award [08/IN.1/B1846]
- Health Service Executive (HSE)
- Health Research Board (HRB) of Ireland
- NIH [P41: P41RR023953, PCD: R01AG10897]
- National Institutes of Health [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
Weight changes are common in aging and Alzheimer's disease (AD) and postmortem findings suggest a relation between lower body mass index (BMI) and increased AD brain pathology. In the current multicenter study, we tested whether lower BMI is associated with higher core AD brain pathology as assessed by cerebrospinal fluid (CSF)-based biological markers of AD in 751 living subjects: 308 patients with AD, 296 subjects with amnestic mild cognitive impairment (MCI), and 147 elderly healthy controls (HC). Based upon a priori cutoff values on CSF concentration of total tau and beta-amyloid (A beta(1-42)), subjects were binarized into a group with abnormal CSF biomarker signature (CSF+) and those without (CSF-). Results showed that BMI was significantly lower in the CSF+ when compared with the CSF- group (F = 27.7, df = 746, p < 0.001). There was no interaction between CSF signature and diagnosis or apolipoprotein E (ApoE) genotype. In conclusion, lower BMI is indicative of AD pathology as assessed with CSF-based biomarkers in demented and nondemented elderly subjects. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据